Inherited gene mutations found in pancreatic cancer families in Spain
Full article: https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(20)30050-5/fulltext
This study looked for inherited mutations in genes known to be linked to hereditary pancreatic cancer. The results provide additional evidence that most hereditary pancreatic cancer is due to inherited mutations in genes that were previously associated with other forms of cancer. (10/29/20)
Questions To Ask Your Health Care Provider
- Do I meet criteria for genetic counseling and testing for high-risk genes linked to pancreatic cancer?
- What genetic tests should I have?
- Can you refer me to a genetic counselor?
- What are the benefits and risks of genetic testing?
- What do my genetic test results mean?
- Can you provide a copy of my genetic test results?
- How will genetic testing affect my medical options?
Open Clinical Trials
The following are studies looking at risk management for pancreatic cancer:
A number of other clinical trials for pancreatic cancer screening and prevention may be found here.
The following are treatment studies enrolling people diagnosed with pancreatic cancer:
- NCT04548752: Adding Pembrolizumab to Olaparib to Treat Pancreatic Cancer in People with an Inherited BRCA Mutation. This study is researching whether adding the drug pembrolizumab to the PARP inhibitor olaparib works better than olaparib alone for treating metastatic pancreatic cancer in people with an inherited BRCA1 or BRCA2 mutation.
- NCT05252390: NUV-868 Alone and in Combination With PARP Inhibitors in Patients With Advanced Solid Tumors. This study will test how safe and effective the experimental drug NUV-868 is by itself and in combination with a PARP inhibitor in people with different types of advanced cancers.
- NCT04493060: Treating Metastatic Pancreatic Cancer with an Inherited or Tumor BRCA1/2 or PALB2 Mutation with Niraparib and Dostarlimab. This study looks at how well the PARP inhibitor niraparib and the immunotherapy drug dostarlimab work together in treating patients with metastatic pancreatic cancer, who have an inherited or tumor mutation in BRCA1, BRCA2, PALB2, BARD1, RAD51C or RAD51D.
- NCT04150042: SHARON: A Clinical Trial for Metastatic Cancer With an Inherited BRCA or PALB2 Mutation Using Chemotherapy and Patients’ Own Stem Cells. This study looks at whether melphalan, BCNU, vitamin B12b, and vitamin C, followed by autologous (self) bone marrow stem cell infusion is safe and effective for treating patients with advanced pancreatic cancer or stage 4, HER2-negative breast cancer for people with a BRCA1, BRCA2 or PALB2 inherited mutation.
- NCT04666740: Pembrolizumab and Olaparib for Metastatic Pancreatic Cancer with Homologous Recombination Deficiency or Exceptional Response to Platinum Chemotherapy. This is a study for people with metastatic pancreatic cancer with a tumor test result called HRD-positive, or whose disease has responded well to first-line or second-line platinum therapy. The study will compare the combination of the immunotherapy pembrolizumab and the PARP inhibitor olaparib to olaparib alone.
- NCT04858334: Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation (APOLLO). The purpose of EA2192 / APOLLO is to compare the usual approach (observation) to treatment for one year with olaparib, in patients with a BRCA1, BRCA2 or PALB2 mutation.
- NCT04550494: Treating Metastatic Solid Tumors with an Inherited or Acquired Gene Mutation Using the PARP Inhibitor Talazoparib. This study is looking whether the drug talazoparib is safe and effective for treating people with advanced breast, gastric, ovarian, pancreatic, or other cancers with an inherited mutation or an acquired mutation in certain DNA repair genes, such as BRCA1, BRCA2, ATM, CHEK2, PALB2 and others.
The following are vaccine studies enrolling people with pancreatic cancer:
- NCT05111353: Neoantigen Vaccines in Pancreatic Cancer in the Window Prior to Surgery. This study will look at the safety of an neoantigen vaccines in pancreatic cancer patients following neoadjuvant chemotherapy. Participants will be placed in one of two groups. Group 1 will receive the vaccine following neoadjuvant chemotherapy and surgery. Group 2 will receive the vaccine after neoadjuvant chemotherapy and before surgery.
Other clinical trials for people with pancreatic cancer can be found here.
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.